DaVita stock holds above $180 as Q2 earnings and analyst targets shape the outlook
Published on 08/27/2026 at 21:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DaVita Inc. (US23918K1088) stock is trading above $180 in late August 2026 after a solid second quarter earnings performance and fresh institutional buying interest in the kidney-care specialist. As of August 26, 2026, the shares closed at $180.05, up 1.27% on the day, before easing slightly in after-hours trading.
Q2 2026 results show earnings leverage
For Q2 2026, DaVita reported revenue of $3.55 billion, which was 5.2% higher than in the prior-year quarter. Adjusted earnings per share from continuing operations reached $4.02, marking a 36.3% increase compared with the same period a year earlier. Those numbers point to meaningful earnings leverage as the company manages costs and mix within its dialysis and kidney-care network.
The contrast between revenue growth and the stronger jump in earnings indicates that margins expanded during Q2 2026. Revenue rising 5.2% while adjusted EPS climbed 36.3% suggests that operating efficiencies and reimbursement dynamics together boosted profitability over the past year. For investors, that level of earnings growth against mid-single-digit top-line expansion is a key part of the current DaVita story.
Analyst targets and institutional interest
Market data compiled in recent reporting shows that DaVita shares currently carry a consensus rating of Hold and an average price target of $221.75. That target sits more than $40 above the recent closing level of around $180, implying a double-digit percentage gap between where the stock trades and where analysts collectively expect it could go over time if the company continues to execute on its strategy.
Recent filings discussed in those same reports highlight continued institutional interest in DaVita. Several investment managers have disclosed new or increased positions, including allocations ranging from tens of thousands of shares to multi-million-dollar stakes. One overview notes a price opening at $180.34 during the latest trading session, reinforcing the picture of the stock consolidating in the low-$180s while institutional investors adjust their positions.
From a performance standpoint, one governance and market snapshot for DaVita shows the shares at $180.30, with a year-to-date change of 58.58% as of August 27, 2026. That means DaVita has added more than half again to its market value since the start of the year, putting its 2026 trajectory well ahead of many broader health-care benchmarks and underscoring how strongly the stock has responded to recent financial results.
Read more on DaVita stock
Go deeper
Further details on DaVita's most recent share price, daily performance, and market history are available on a real-time quote page that tracks the DVA ticker in U.S. trading.
More on DaVita stock
Investor Relations
DaVita's corporate website provides access to investor presentations, financial reports, and information on its kidney-care network and strategic priorities.
Kidney-care services underpin the business
DaVita generates most of its revenue by operating dialysis centers and related kidney-care services across the United States and in selected international markets. The company works with patients suffering from chronic kidney disease and end-stage renal disease, providing recurring treatments that are critical to long-term health outcomes. That recurring-care model helps support relatively stable demand, which in turn contributes to the company’s ability to translate operational efficiencies into earnings growth.
In practice, DaVita's network includes hundreds of outpatient dialysis centers along with programs focused on home dialysis, patient education, and coordination with nephrologists and hospitals. Revenue trends, such as the 5.2% year-over-year increase in Q2 2026, reflect both volume growth and the reimbursement environment in its core markets. As health systems in the U.S. continue to emphasize chronic-disease management, DaVita's services remain central to patient care and an important component of payer spending.
Shares hold above $180
DaVita stock is listed on the New York Stock Exchange under the ticker DVA and trades in U.S. dollars. As of the closing auction on August 26, 2026, the shares finished at $180.05. Intraday quotes around August 27, 2026 show prices fluctuating close to that level, with one snapshot indicating the stock at $180.30 and another opening print at $180.34, signaling a relatively tight trading range in the low-$180s.
With the shares up 58.58% year-to-date as of August 27, 2026, DaVita has delivered a strong advance in 2026. Combined with Q2 2026 adjusted EPS of $4.02, up 36.3% from the prior-year quarter, and the consensus price target of $221.75 that stands well above the current share price, the stock’s recent behavior reflects a market that is already pricing in improved fundamentals while still leaving room for further appreciation if earnings momentum continues.
Fact box
Company: DaVita Inc.
ISIN: US23918K1088
Ticker: DVA
Exchange: New York Stock Exchange
Price (as of August 26, 2026, 4:00 p.m. ET): $180.05 USD
Sector / Industry: Health care - providers and services
Index membership: S&P 500
